Vall d'Hebron Institute of Oncology (VHIO) at ENA 2026
Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website
Vall d'Hebron Institute of Oncology (VHIO) brings 13 presentations to ENA 2026 in Barcelona, its home city. Its program spans immune engagers, next-generation cell therapies, early-phase trial methods and patient-derived breast cancer models. Work on the MYC inhibitor OMO-103 covers a phase Ib study with gemcitabine and nab-paclitaxel in metastatic pancreatic cancer and immunotherapy vulnerabilities in KRAS-mutant NSCLC.
| Organization | ENA 2026 Attendance |
|---|---|
Vall d'Hebron Institute of Oncology (VHIO) Barcelona, Spain | |
Barcelona cancer research institute at Vall d'Hebron University Hospital, combining translational research with an early-phase clinical trials unit. | Session Wed Nov 18 1:30–1:35pm Session Wed Nov 18 1:35–2:20pm Session Wed Nov 18 2:20–3:50pm Talk Thu Nov 19 3:20–3:40pm Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Session Fri Nov 20 8–9:30am Talk Fri Nov 20 8:40–9am Talk Fri Nov 20 9:45–10am Talk Fri Nov 20 12–12:10pm Session Fri Nov 20 3–4:50pm Poster Fri Nov 20 10:45–11:15am 1:30–3pm Poster Fri Nov 20 10:45–11:15am 1:30–3pm Poster Fri Nov 20 10:45–11:15am 1:30–3pm |
Instantly find 20 buyers from Vall d'Hebron Institute of Oncology (VHIO)
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction